New details have emerged regarding the settlement reached by OxyContin maker Purdue Pharma, outlining the financial and structural aspects of the agreement.

Victims of the opioid crisis seeking compensation from Purdue Pharma's bankruptcy settlement are reportedly facing significant challenges due to complex paperwork, delaying or preventing them from receiving justice.

Consulting firm McKinsey & Company has agreed to contribute $125 million to the Purdue Pharma bankruptcy trust, settling claims related to its advisory role in the pharmaceutical company's opioid sales practices.

Purdue Pharma is expected to forfeit $225 million as part of its sentence in a criminal opioids case, with the settlement funds distributed to state, local, and tribal governments, as well as individual victims.

OxyContin maker Purdue Pharma is facing a criminal sentence that could mark the final step before the company dissolves. This development is a significant moment in the ongoing legal battles surrounding the opioid crisis.

Purdue Pharma is scheduled to be sentenced in its criminal opioids case, marking a significant development in the ongoing legal proceedings.